As per IMS MAT December 2016 sales data, Tobramycin inhalation solution had sales of $133.6 million in the US market.
Thallion Pharmaceuticals had a turnover of Canadian dollar 3.1 million for the year ended December 31, 2016.
Sun gained the plant along with its acquisition of Ranbaxy Laboratories in 2015 and has been attempting to fix quality control problems there that the US Food and Drug Administration (FDA) identified in 2013.
As stipulated under the Drugs (Prices Control) Order (DPCO) 2013, NPPA fixes ceiling price of essential medicines of Schedule I.
The other pharma players the prices whose cancer medicines have been reduced are Natco Pharma and Emcure pharmaceuticals among others, it added.
Under the agreements, Cipla will divest its 100 per cent stake in Cipla Agrimed Proprietary South Africa and Cipla Vet Proprietary, South Africa, it said.
Dr Reddy's Laboratories on Thursday said it has received an unfavourable ruling in a US court regarding a patent infringement case over Aloxi.
Dr Reddy's is recalling Olanzapine tablets USP of 2.5 mg while Aurobindo is recalling Pantoprazole Sodium for Injection, 40mg per vial from the market, the notification issued by the US regulator said.
Among the key issues of concern for the US pharma sector in India are unpredictable IP environment, high tariffs and taxes on medicines among others.
Drug firm Ajanta Pharma on Thursday said the US health regulator has issued one observation for its Paithan facility in Aurangabad after the inspection.
The recall is being initiated by Sun Pharmaceutical Industries Inc for 2,71,212 bottles of bupropion hydrochloride extended-release tablets, USP (SR) in the strengths of 150 mg and 200 mg, the FDA said.
Mr Piramal curtailed his presence in healthcare after he sold erstwhile Piramal Healthcare's domestic formulations division for $3.7 billion to Abbott in 2010.
With the growth momentum hit hard by the notes ban, Nomura had earlier projected GDP growth to dip to 6.9 per cent in 2017 from 7.1 per cent in 2016, with a sharp slowdown in the first half of the current year.
In respect of medicines not under price control, manufacturers are allowed to increase the maximum retail price by 10 per cent annually.
The FDA had inspected the Kothur formulation facility between January 16-24, 2017, Natco Pharma said in a statement.
Natco Pharma said it will provide due justifications and corrective action plan within next 15 working days to the address the USFDA observations.
There were media reports saying the company has got import alert from USFDA for its Paithan unit at Aurangabad for which BSE had sought for a clarification from Ajanta Pharma.